Krebs Biochemicals & Industries Limited
NSE: KREBSBIO BSE: KREBSBIO
Prev Close
57.9
Open Price
59.98
Volume
3,983
Today Low / High
57.69 / 59.98
52 WK Low / High
53.05 / 113.5
Range
56 - 62
Prev Close
57.61
Open Price
62
Volume
49
Today Low / High
57.07 / 62
52 WK Low / High
51 / 113.9
Range
56 - 62
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 58.99 (target range: 56 - 62), reflecting a change of 1.09 (1.88256%). On the BSE, it is listed at 58.8 (target range: 56 - 62), showing a change of 1.19 (2.06561%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Krebs Biochemicals & Industries Limited Graph
Krebs Biochemicals & Industries Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Krebs Biochemicals & Industries Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 58.99, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 58.80 | 59.39 | 53.45 - 65.33 |
| 59.98 | 47.98 - 71.97 | ||
| 60.56 | 42.39 - 78.73 | ||
| Bearish Scenario | 58.80 | 58.21 | 52.39 - 64.03 |
| 57.62 | 46.10 - 69.15 | ||
| 57.04 | 39.93 - 74.15 |
Overview of Krebs Biochemicals & Industries Limited
ISIN
INE268B01013
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
12,492
Market Cap
1,292,341,525
Last Dividend
0
Official Website
IPO Date
2016-10-27
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of KREBSBIO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2005-09-14 | September 14, 05 | 2.89781 | 3 | 2005-09-16 | 2005-10-01 | 2005-06-09 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 43.31 Cr | 5.56 Cr | 37.76 Cr | 0.8717 | 1.52 Cr | 0.00 Cr | -21.72 Cr | -26.94 Cr | -12.50 | -14.32 Cr | -0.6220 |
| 2024-03-31 | 50.42 Cr | 61.30 Cr | -10.87 Cr | -0.2157 | 0.00 Cr | 0.60 Cr | -15.49 Cr | -19.73 Cr | -9.15 | -8.27 Cr | -0.3913 |
| 2023-03-31 | 52.13 Cr | 27.72 Cr | 24.42 Cr | 0.4684 | 0.00 Cr | 0.86 Cr | -21.94 Cr | -24.69 Cr | -11.45 | -15.16 Cr | -0.4736 |
| 2022-03-31 | 59.70 Cr | 65.47 Cr | -5.76 Cr | -0.0965 | 1.64 Cr | 1.14 Cr | -39.49 Cr | -44.53 Cr | -20.65 | -32.85 Cr | -0.7458 |
| 2021-03-31 | 38.61 Cr | 52.23 Cr | -13.63 Cr | -0.3529 | 1.47 Cr | 0.67 Cr | -23.67 Cr | -28.36 Cr | -14.45 | -16.96 Cr | -0.7346 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.14 Cr | 169.04 Cr | 315.27 Cr | -146.2388 Cr | 212.21 Cr | 212.07 Cr | 6.03 Cr | 146.47 Cr | 0.00 Cr | 0.00 Cr | 2.85 Cr | 103.5260 Cr |
| 2024-03-31 | 0.14 Cr | 178.17 Cr | 297.39 Cr | -119.2167 Cr | 238.68 Cr | 238.61 Cr | 10.24 Cr | 149.74 Cr | 0.00 Cr | 0.00 Cr | -0.47 Cr | 61.8339 Cr |
| 2023-03-31 | 0.09 Cr | 174.98 Cr | 274.44 Cr | -99.4623 Cr | 183.24 Cr | 183.15 Cr | 12.36 Cr | 149.05 Cr | 0.00 Cr | 0.00 Cr | 2.09 Cr | 49.1047 Cr |
| 2022-03-31 | 0.03 Cr | 189.81 Cr | 264.90 Cr | -75.0932 Cr | 188.10 Cr | 188.07 Cr | 25.86 Cr | 144.93 Cr | 0.00 Cr | 0.00 Cr | 0.04 Cr | 78.0640 Cr |
| 2021-03-31 | 0.71 Cr | 159.22 Cr | 201.95 Cr | -42.7329 Cr | 111.14 Cr | 125.55 Cr | 16.89 Cr | 128.21 Cr | 0.00 Cr | 0.00 Cr | 0.04 Cr | 48.1924 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -7.8910 Cr | -4.9696 Cr | 12.8648 Cr | -11.4542 Cr | 0.0042 Cr | 0.1416 Cr | -3.5632 Cr | -26.9240 Cr | 18.7789 Cr | 0.0000 Cr | 3.7649 Cr |
| 2024-03-31 | 2.3040 Cr | -7.8167 Cr | 5.5641 Cr | -7.0501 Cr | 0.0516 Cr | 0.1374 Cr | -9.4150 Cr | -19.7284 Cr | 10.2535 Cr | 0.0000 Cr | 2.1492 Cr |
| 2023-03-31 | -24.7132 Cr | -12.6450 Cr | 37.3433 Cr | -35.5836 Cr | -0.0148 Cr | 0.0858 Cr | -10.8704 Cr | -24.6919 Cr | 40.3165 Cr | 0.0000 Cr | 13.6170 Cr |
| 2022-03-31 | -17.2162 Cr | -22.8995 Cr | 39.5056 Cr | -40.7363 Cr | -0.6101 Cr | 0.1006 Cr | -23.5201 Cr | -44.5268 Cr | 32.3835 Cr | 0.0000 Cr | -8.9622 Cr |
| 2021-03-31 | -14.5748 Cr | -22.5493 Cr | 37.6605 Cr | -40.0812 Cr | 0.5364 Cr | 0.7107 Cr | -25.5064 Cr | -28.3586 Cr | 33.4906 Cr | 0.0000 Cr | -1.6049 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 7.27 Cr | 0.00 Cr | 7.27 Cr | 0.9998 | -1.34 Cr | -3.13 Cr | -1.45 | 0.30 Cr | -0.4298 |
| 2025-09-30 | 4.17 Cr | 4.32 Cr | -0.15 Cr | -0.0356 | -4.42 Cr | -6.14 Cr | -2.85 | -2.79 Cr | -1.4740 |
| 2025-06-30 | 5.48 Cr | 0.29 Cr | 5.19 Cr | 0.9472 | -3.69 Cr | -5.32 Cr | -2.47 | -2.08 Cr | -0.9714 |
| 2025-03-31 | 6.10 Cr | 0.57 Cr | 5.53 Cr | 0.9071 | -6.98 Cr | -8.27 Cr | -3.84 | -5.07 Cr | -1.3554 |
| 2024-12-31 | 11.47 Cr | 1.31 Cr | 10.16 Cr | 0.8858 | -6.43 Cr | -7.74 Cr | -3.59 | -4.46 Cr | -0.6749 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 0.15 Cr | 0.00 Cr | 0.15 Cr | 0.05 Cr | 5.77 Cr | 9.78 Cr | 143.54 Cr | 165.91 Cr | 326.75 Cr |
| 2025-09-30 | 0.13 Cr | 0.03 Cr | 0.13 Cr | 0.14 Cr | 5.77 Cr | 10.17 Cr | 145.39 Cr | 168.03 Cr | 325.74 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 0.14 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 146.24 Cr |
| 2025-03-31 | 0.14 Cr | 0.20 Cr | 0.34 Cr | 0.05 Cr | 6.03 Cr | 10.26 Cr | 146.47 Cr | 169.04 Cr | 315.27 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 0.14 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 130.15 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -5.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -8.27 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | -7.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -5.76 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -5.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-01-31 | January 31, 19 | 207:200 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,764.20 | ₹4,232,906,754,074.00 | ₹1,200,910.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,395.50 | ₹1,697,804,303,390.00 | ₹348,437.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,418.90 | ₹1,495,556,554,816.00 | ₹359,909.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,306.50 | ₹1,087,750,340,235.00 | ₹2,296,180.00 |
| Lupin Limited | LUPIN | ₹2,292.20 | ₹1,047,633,964,600.00 | ₹1,104,211.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹919.65 | ₹925,383,088,904.00 | ₹564,412.00 |
| Mankind Pharma Limited | MANKIND | ₹2,155.70 | ₹889,883,893,710.00 | ₹802,349.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,211.50 | ₹703,641,166,265.00 | ₹3,039,172.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,625.00 | ₹672,553,125,000.00 | ₹231,439.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,085.00 | ₹588,388,686,765.00 | ₹455,450.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,076.35 | ₹581,074,632,036.00 | ₹2,096,370.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,524.50 | ₹386,772,080,341.00 | ₹102,371.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹3,021.30 | ₹377,468,000,791.00 | ₹185,671.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,085.90 | ₹334,844,408,201.00 | ₹172,351.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,430.80 | ₹271,240,390,232.00 | ₹90,076.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,377.10 | ₹223,767,965,930.00 | ₹212,770.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,869.00 | ₹221,725,000,000.00 | ₹2,566.00 |
| Eris Lifesciences Limited | ERIS | ₹1,380.20 | ₹188,006,552,958.00 | ₹30,161.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹978.20 | ₹175,205,274,834.00 | ₹5,721,405.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,331.00 | ₹171,035,250,259.00 | ₹27,190.00 |
| Granules India Limited | GRANULES | ₹599.95 | ₹145,589,096,164.00 | ₹775,187.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹739.90 | ₹145,437,055,448.00 | ₹143,343.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹897.35 | ₹142,113,093,368.00 | ₹305,229.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,727.00 | ₹131,272,198,992.00 | ₹21,410.00 |
| Cohance Lifesciences Limited | COHANCE | ₹310.50 | ₹118,787,096,970.00 | ₹467,931.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹907.55 | ₹111,389,056,800.00 | ₹41,715.00 |
| Viyash Scientific Limited | VIYASH | ₹219.27 | ₹95,646,792,922.00 | ₹684,479.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,136.00 | ₹85,254,425,952.00 | ₹7,919.00 |
| Strides Pharma Science Limited | STAR | ₹863.60 | ₹79,600,355,810.00 | ₹85,803.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹478.65 | ₹73,282,300,062.00 | ₹136,589.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹708.30 | ₹64,205,475,507.00 | ₹171,833.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹327.45 | ₹64,043,265,649.00 | ₹194,387.00 |
| FDC Limited | FDC | ₹364.30 | ₹59,311,713,601.00 | ₹46,671.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹130.92 | ₹42,486,366,301.00 | ₹619,172.00 |
| Innova Captab Limited | INNOVACAP | ₹668.35 | ₹38,246,281,297.00 | ₹12,022.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹316.30 | ₹34,465,713,320.00 | ₹32,182.00 |
| Suven Life Sciences Limited | SUVEN | ₹149.76 | ₹34,066,506,240.00 | ₹112,567.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹369.70 | ₹33,742,519,000.00 | ₹60,664.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹630.60 | ₹31,983,467,613.00 | ₹129,611.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,914.20 | ₹31,658,982,513.00 | ₹9,690.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹279.30 | ₹28,008,903,926.00 | ₹39,032.00 |
Key Executives
Gender: male
Year Born: 1976
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Krebs Biochemicals & Industries Limited
The CEO is Manish Kumar Jain.
The current price is ₹59.94.
The range is ₹53.05-113.5.
The market capitalization is ₹129.23 crores.
The P/E ratio is -5.65.
The company operates in the Healthcare sector.
Overview of Krebs Biochemicals & Industries Limited (ISIN: INE268B01013) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹129.23 crores and an average daily volume of 12,492 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.